APONTIS PHARMA AG Receives Buy Rating from First Berlin Equity Research

First Berlin Equity Research GmbH initiated coverage on APONTIS PHARMA AG, a leading specialty pharmaceutical company in Germany. Analyst Christian Orquera issued a BUY recommendation with a target price of EUR 17.00, sighted over 12 months. The report highlights APONTIS's innovative approach in developing 'single pills' for cardiovascular and respiratory diseases.

2023 was challenging for APONTIS due to revenue setbacks that led to significant EBITDA losses. However, the appointment of a new CEO, Mr. Wohlschlegel, who brings over 26 years of experience from Merck, has started to show positive results. His initiatives include staff reductions, a modern marketing strategy, and a marketing deal with Novartis for asthma drugs, resulting in substantial anticipated annual savings.

The strong financial performance in Q1 2024 suggests APONTIS is well-positioned to capture the growing single pill market. The projected upside potential from the current level exceeds 100%, making APONTIS a compelling turnaround story.